“To Anticipate”: Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers

Mattia Garutti, Silvia Buriolla, Elisa Bertoli, Maria Grazia Vitale, Ernesto Rossi, Giovanni Schinzari, Alessandro Marco Minisini, Fabio Puglisi

Research output: Contribution to journalReview articlepeer-review

Abstract

Despite surgical resection and adjuvant therapies, stage III melanomas still have a substantial risk of relapse. Neoadjuvant therapy is an emerging strategy that might offer superior efficacy compared to adjuvant therapy. Moreover, neoadjuvant therapy has some virtual advantages: it might allow for less demolitive surgery, permit the in vivo evaluation of drug efficacy, help tailor adjuvant treatments, and play a crucial role in innovative translational research. Herein, we review the available literature to explore the scientific background behind the neoadjuvant approach. We also discuss published clinical trials with a focus on predictive biomarkers and ongoing studies. Finally, we outline a possible framework for future neoadjuvant clinical trial development based on the International Neoadjuvant Melanoma Consortium guidelines.

Original languageEnglish
Article number1941
Pages (from-to)1-19
Number of pages19
JournalCancers
Volume12
Issue number7
DOIs
Publication statusPublished - Jul 2020

Keywords

  • Adjuvant
  • BRAF
  • Immunotherapy
  • MEK
  • Melanoma
  • Neoadjuvant

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of '“To Anticipate”: Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers'. Together they form a unique fingerprint.

Cite this